William Blair research analyst Andy Hsieh was quoted in CNBC, discussing a “new class” of cancer treatments from biotech and life sciences companies, specifically focused on antibody-drug conjugates, or ADCs.

“It's kind of like FOMO, right? Everyone wants to gain exposure to [ADCs] and basically make it a cornerstone of their entire corporate strategy,” Hsieh told the publication.